

FINAL EVALUATION REPORT

AS PER CLAUSE 35 OF PPRA, 2004 AS AMENDED UP TO THE DATE

1- NAME OF PROCURING AGENCY: WAPDA HOSPITAL GUJRANWALA

2- METHOD OF PROCUREMENT SINGLE STAGE TWO ENVELOPE

3- TITLE OF PROCUREMENT: BULK SUPPLY OF Drugs/Medicines.

4- TENDER INQUIRY NO. PRD(L)/WAPDA/001(2022-23)

5- PPRA REFERENCE NO.(TSE):TS485177E

6- DATE & TIME OF BID CLOSING: 27-07-2022 11:00 AM

7- DATE & TIME OF BID OPENING: 27-07-2022 11:30 AM

8- NO. OF BIDS RECEIVED: 27

9- CRITERIA FOR BIDS EVALUATION: As Per Clause 28 & 29 of Bidding Doc.

FINANCIAL BID OPENING Date: -10-10-2022.

PRELIMINARY TECHNICAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

Sr. No	Bidder Name	Tender Purchase Receipt/2000	Original Bid Security Rs.100000/(One Lac)-in the shape of CDR/Pay Order /Demand Draft	Bidder's NTN Certificate along with ATL Verification	Bidders Valid Drugs Manufacturing and licence Issued by DRAP/ DSL	Sole Agency Certificate in case of imported Products	Completely & Accurately filled BID Form-1 (Bidders Profile)	Completely & Accurately filled BID Form-2 (Letter of Intention)	Completely & Accurately filled BID Form-3 (Technical Evaluation Form) Separately filled on firm Letter	Completely & Accurately filled BID Form-5 (Manufacturer authorized Firm)	Bid Form -6 (Affidavit on Rs.100 Stamp Paper)	(Bid Form-7) Integrity Pact	Status
1	Getz Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
2	Cheisi Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
3	Sante (Pvt)Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
4	Platinum Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
5	Hiranis Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
6	Kaizen Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
7	Barrett Hodgson	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
8	Phamatec	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
9	Sanofi Aventis Pakistan Limited	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
10	Bayer Pakistan (Pvt) Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified

Wapda Hospital - C


48837


11	The Searle Company Limited	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
12	FerozSons Laboratories Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
13	B&F Biosciences Limited	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
14	Novo Nordisk Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
15	AGP Limited	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
16	Next Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
17	Pharvevo (Pvt)Ltd.	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
18	Macter International Limited.	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
19	Helix Pharma (Pvt)Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
20	Scilife Pharma (Pvt) Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
21	Maple Pharma (Pvt)Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
22	Hilton Pharma (Pvt)Ltd	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
23	Servier Research & Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
24	Bosch Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
25	Highnoon Laboratories	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
26	Shaigan Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified
27	PDH Pharma	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Qualified


Dr.Mehwish Khalid
Pharmacist
(Member)


Speed Ahmed
Assistant Director (Admin)
(Member)


Tariq Aziz
Assistant Manager (A&F)
(Member)


Dr.Zahid Hussain Burdi
Regional Procurement Officer
Convenor

Counter Signature

Dr Muhammad Zahid Akram
M.S Wapda Hospital Gujranwala.

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

Sr #	Generic Name/Brand Name		Potency	Bidder's Name	Brand Name	Technical Marks (50)	Technical Status	Pack Size	Offered Price		Financial status	Rule/Regulation/SBD*/Policy/ Basis for Rejection / Acceptance as per Rule 35 of PP Rules, 2004.
									Per Pack	Per Unit		
1	Esomeprazole	Capsule	40mg									
				Getz	Nexum	47	Qualified	14	95	6.7857	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Esomega	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	EsoNext	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Maple Pharma	Esomap	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				FerozSons	Fasteso	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Macter	E-Sante	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Bosch Pharma	Somezol	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Esso	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Esorid	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Axesom	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Acireg	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
2	Esomeprazole	Capsule	20mg									
				Getz	Nexum	47	Qualified	14	73	5.2143	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Esomega	42	Qualified	14	97.12	6.9371		Conformity with Bid Evaluation Criteria
				Highnoon	Axesom	35	Qualified	14	91.51	6.5364		Conformity with Bid Evaluation Criteria
				Next Pharma	EsoNext	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Maple Pharma	Esomap	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Fasteso	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Macter	E-Sante	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Esso	35	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Esorid	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
3	Famotidine	Tablet	20mg									

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				FerozSons	H2F	40	Qualified	10	31.55	3.155	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Shaigan	Famot	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Acicon	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
4	Famotidine	Syrup	10mg									
				Barrett Hodgson	Acicon	35	Qualified	1	49.5	49.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
5	Lansoprazole	Capsule	30mg			0						
				Pharmatec	Lanzol	42	Qualified	14	275	19.643	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Selanz	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Inhibtol	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
6	Omeprazole	Capsule	20mg									
				Getz	Risek	47	Qualified	14	66	4.7143	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmatec	Prazol	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				FerozSons	Omega	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				The Searle	Lovanzo	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Omecap	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Zoltar	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Omsta	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
7	Omeprazole	Capsule	40mg									
				Getz	Risek	47	Qualified	14	105	7.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmatec	Prazol	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				FerozSons	Omega	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				The Searle	Lovanzo	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Omecap	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Maple Pharma	Omsik	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Zoltar	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Omsta	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
8	Omeprazole	Infusion	40mg									
				The Searle	Lovanzo	37	Qualified	1	243.79	243.79	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmevo	Zoltar	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Viber	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten mark]

[Handwritten mark]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

9	Pantoprazole	Capsule	20mg										
				Hilton	Zopent	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Baropent DR	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
10	Pantoprazole	Capsule	40mg										
				Hilton	Zopent	36	Qualified	20	252.88	12.644	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Hiranis Pharmaceutical	Glovar	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Baropent DR	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
11	Sucralfate	Suspension	500mg										
				Highnoon	Ulsanic	41	Qualified	1	246.5	246.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
12	Sucralfate	Tablet	1gm	No Bid Received									
13	Lactulose	Syrup	3.35gm	No Bid Received									
14	Sod. Biphosphate + Sod.Phosphate + Sod. Contents	Solution		No Bid Received									
15	Sod. Picosulphate	Drops	7.5mg	No Bid Received									
16	Sulfolax	Drops											
				Highnoon	Skilax	43	Qualified	1	47.5	47.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
17	Doxylamine Succinate+Pyridoxine*	Tablet		No Bid Received									
18	Loperamide	Tablet	2mg	No Bid Received									
19	Metronidazole	Suspension	200mg	No Bid Received									
				The Searle	Metrozine	37	Qualified	1	53.34	53.34	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Sanofi Aventis	Flagyl	46	Qualified	1	87.98	87.98		Conformity with Bid Evaluation Criteria	
20	Metronidazole	Infusion	500mg										
				Bosch Pharm	Flazol	37	Qualified	1	79	79	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Sanofi Aventis	Flagyl	46	Qualified	1	130.65	130.65		Conformity with Bid Evaluation Criteria	
21	Metronidazole	Tablet	400mg			0							
				The Searle	Metrozine	39	Qualified	100	180	8	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
22	Metronidazole + Diloxanide	Suspension		No Bid Received									

[Handwritten signatures and marks on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

23	Metronidazole + Diloxanide	Tablet		No Bid Received								
24	ORS*	Sachet										
				The Searle	Peditral	42	Qualified	1	14.54	14.54	Lowest Evaluated	Conformity with Bid Evaluation Criteria
25	Zinc Solution	Solution	10mg									
				Barrett Hodgson	Zincday	44	Qualified	1	36.28	36.28	Lowest Evaluated	Conformity with Bid Evaluation Criteria
26	Drotaverine	Injection	40mg									
				Sanofi Aventis	Nospa	46	Qualified	25	974.75	38.99	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Relispa	42	Qualified					Rate Not Quoted
27	Drotaverine	Tablet	80mg	No Bid Received								
28	Drotaverine	Tablet	40mg									
				Sanofi Aventis	Nospa	46	Qualified	20	128.88	6.444	Lowest Evaluated	Conformity with Bid Evaluation Criteria
29	Hyoscine+Paracetamole*	Tablet	mg	No Bid Received								
30	Itiopride	Tablet	50mg									
				FerozSons	Dynetic	42	Qualified	10	54.9	5.49	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmatec	Itolium	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Helix	Nogerd	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Itotab	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Gutset	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
31	Mebaverine	Tablet	200mg	No Bid Received								
32	Al(OH) ₂ +Mg(OH) ₂ + Simethecon	Suspension	120ml	No Bid Received								
33	Albendazole	Suspension	100mg	No Bid Received								
34	Aceclofenac	Tablet	100mg									
				Maple Pharma	Acelo	38	Qualified	30	90	3	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Platinum	Acelish	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
35	Celecoxib	Tablet	100mg	No Bid Received								
36	Codiene+ Paracetamole + Caffein	Tablet	15/500/15mg	No Bid Received								

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

37	Diclofenac Potassium	Tablet	50mg										
				Hilton	Maxit	27	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
				PDH	Peplofen P	32	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
				Kaizen	Velflex	33	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Artimov-K	30	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
38	Diclofenac Sod.	Tablet	50mg	No Bid Received									
39	Diclofenac Sod.	Gel	1%										
				Platinum	Fastaid Gel	38	Qualified	1	35.61	35.61	Lowest Evaluated		Conformity with Bid Evaluation Criteria
40	Diclofenac Sod.	Injection	75mg	No Bid Received									
41	Etoricoxib*	Tablet	60mg										
				FerozSons	Flexia	42	Qualified	10	105.64	10.564	Lowest Evaluated		Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Etoxib	19	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
42	Flurbiprofen	Tablet	100mg										
				Kaizen	Tornil	31	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Dentifen	19	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
43	Ibuprofen	Suspension	100mg										
				Kaizen	Torfen	37	Qualified	1	52	52	Lowest Evaluated		Conformity with Bid Evaluation Criteria
44	Ibuprofen	Tablet	400mg	No Bid Received									
45	Ketorolac*	Injection	30mg	No Bid Received									
46	Mefanamic Acid	Tablet	500mg										
				Pharmatec	Zopan DS	42	Qualified	200	510	2.55	Lowest Evaluated		Conformity with Bid Evaluation Criteria
47	Methyl Salicylate+Menthol+Eucalyptol*	Cream		No Bid Received									
48	Naproxen	Tablet	500mg	No Bid Received									
49	Naproxen Sod.	Tablet	550mg	No Bid Received									
				Hiranis Pharmaceutical	Gia	20	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

50	Nimesulide	Tablet	100mg										
				Pharmevo	Nise	37	Qualified	20	48	2.4	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Hilton	Unix	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
51	Paracetamole	Tablet	500mg										
52	Paracetamole	Infusion	1gm										
				Bosch Pharm	Bofalgan	45	Qualified	1	98.68	98.68	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
53	Paracetamole	Suspension	250mg									Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Febrol DS	35	Qualified	1	45.78	45.78	Lowest Evaluated		
54	Paracetamole	Drops	100mg/ml	No Bid Received									
55	Paracetamole + Caffeine	Tablet	500mg	No Bid Received									
56	Paracetamole + Dextropropoxyphene	Tablet		No Bid Received									
57	Paracetamole + Orphenadrine	Tablet	450/35mg										
				Shaigan	Acetofen	35	Qualified	100	295.65	2.9565	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				AGP	Sinaxamol	40	Qualified	100	428.82	4.2882		Conformity with Bid Evaluation Criteria	
				The Searle	Nuberol	42	Qualified	100	362.83	3.6283		Conformity with Bid Evaluation Criteria	
58	Piroxicam	Tablet	20mg										
				AGP	Briax	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
59	Piroxicam Beta Cyclodextrin	Tablet	20mg										
				Chiesi	Brexin	50	Qualified	20	358.19	17.91	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Kaizen	Betadex	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Hiranis Pharmaceutical	Relevo	19	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
60	Serratiopeptidase	Tablet	10mg	No Bid Received									
61	Thiocolchicoside	Capsule	4mg										

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Sanofi Aventis	Muscoril	40	Qualified	20	734.6	36.73	Lowest Evaluated	Conformity with Bid Evaluation Criteria
62	Thiocolchicoside	Injection	4mg									
				Sanofi Aventis	Muscoril	40	Qualified	6	711.36	118.56	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmevo	Thewril	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
63	Allopurinol	Tablet	100mg	No Bid Received								
64	Allopurinol	Tablet	300mg	No Bid Received								
65	Febuxostat	Tablet	40mg									
				Pharmevo	Gouric	36	Qualified	20	150	7.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Febhil	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Hiloric	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Febugout	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barret Hodgson	Baristat	22	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
66	Febuxostat	Tablet	80mg									
				Pharmevo	Gouric	36	Qualified	20	300	15	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Febhil	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
67	Nalbuphine	Injection	10mg									
				Bosch Pharm	Bunail	45	Qualified	5	163.92	32.784	Lowest Evaluated	Conformity with Bid Evaluation Criteria
68	Tramadol	Injection	100/2mlmg									
				AGP	Calfina	36	Qualified	5	204.49	40.898	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Tramal	41	Qualified	5	294.4	58.88		Conformity with Bid Evaluation Criteria
69	Tramadol	Tablet	100mg									
				AGP	Calfina CR	35	Qualified	10	210.93	21.093	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Tramal SR	41	Qualified	10	262.56	26.256		Conformity with Bid Evaluation Criteria
70	Tramadol + Paracetamol	Tablet	37.5/325mg									
				The Searle	Tramal Plus	41	Qualified	10	100.29	10.029	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Calfina Plus	38	Qualified	10	116.1	11.61		Conformity with Bid Evaluation Criteria
				Barret Hodgson	Febrol Fast	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
71	Tizanidine	Tablet	2mg									

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				AGP	Analar	42	Qualified	10	68.96	6.896	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Platinum	Zaniflex	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Barret Hodgson	Terlax	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
72	Tizanidine	Tablet	4mg	No Bid Received									
73	Hydroxy Choloquin sulphate	Tablet	200mg	No Bid Received									
74	Leflunamide	Tablet	10mg	No Bid Received									
75	Leflunamide	Tablet	20mg										
				Hilton	Lefora	37	Qualified	30	636	21.2	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
76	Osseine Mineral Complex	Suspension	250mg										
				Barret Hodgson	Esegrow	35	Qualified	1	48.13	48.13	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Kaizen	Ossvit-D	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Platinum	Ossogin	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Hiranis Pharmaceutical	Osicom D	19	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
77	Osseine Mineral Complex+ Vitamin D	Tablet	830/400IUmg										
				AGP	Osnate-D	39	Qualified	30	274.19	9.1397	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Kaizen	Ossvit-D	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Platinum	Ossogin	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Hiranis Pharmaceutical	Osicom D	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Esegrow	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
78	Alprazolam	Tablet	0.5mg	No Bid Received									
79	Bromazepam	Tablet	3mg	No Bid Received									
80	Diazepam	Injection	10mg	No Bid Received									
81	Midazolam	Injection	5mg	No Bid Received									
82	Cetirizine	Syrup	15mg/5ml										
				Barrett Hodgson	Gixer	39	Qualified	1	30.52	30.52	Lowest Evaluated	Conformity with Bid Evaluation Criteria	

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				AGP	Rigix	39	Qualified	1	98.68	98.68		Conformity with Bid Evaluation Criteria
				Platinum Pharma	Avec	29	Disqualified					Non-Conformity with Bid Evaluation Criteria
				PDH	Cezine	29	Disqualified					Non-Conformity with Bid Evaluation Criteria
83	Cetirizine	Tablet	10mg									
				Barrett Hodgson	Gixer	42	Qualified	10	22.5	2.25	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Rigix	39	Qualified	30	160.22	5.3407		Conformity with Bid Evaluation Criteria
				Bayer Pakistan	Baydol	45	Qualified	100	460.06	4.6006		Conformity with Bid Evaluation Criteria
				PDH	Cezine	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
84	Desloratadine	Tablet	5mg									
				Hiranis Pharmaceutical	Slorit	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
85	Fexofenadine	Tablet	60mg									
				The Searle	Xadine	37	Qualified	20	100	5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Shaigan	Fifex	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Fexadin	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Paltinum	Fexofast	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
86	Fexofenadine	Tablet	120mg									
				The Searle	Xadine	37	Qualified	20	200	10	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				PDH	Fexadin	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Paltinum	Fexofast	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Hirafex	19	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
87	Levocetirizine	Tablet	10mg	No Bid Received								
88	Levocetirizine	Tablet	5mg									
				Kaizen	Welcet	35	Qualified	30	98.8	3.2933	Lowest Evaluated	Conformity with Bid Evaluation Criteria
89	Phenaramine	Syrup	15mg	No Bid Received								
90	Dimenhydrinate	Injection	50mg	No Bid Received								
91	Dimenhydrinate	Syrup	12.5mg									

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				The Searle	Gravinate	42	Qualified	1	34.54	34.54	Lowest Evaluated	Conformity with Bid Evaluation Criteria
92	Domperidone	Suspension	1mg/ml									
				Barrett Hodgson	Domel	42	Qualified	1	33.37	33.37	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Next Pharma	Domflash	35	Qualified	1	78.95	78.95		Conformity with Bid Evaluation Criteria
				PDH	Stominant	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Platinum	Emiset	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
93	Metoclopramide	Injection	10mg	No Bid Received								
94	Ondansetron	Injection	8mg	No Bid Received								
95	Ondansetron	Tablet	8mg	No Bid Received								
96	Prochlorperazine	Tablet	5mg	No Bid Received								
97	Betahistine	Tablet	8mg	No Bid Received								
98	Pregaballine	Capsule	50mg									
				Highnoon	Hilin	38	Qualified	14	84.42	6.03		Conformity with Bid Evaluation Criteria
				Hilton	Zeegab	37	Qualified	14	124.1	8.8643		Conformity with Bid Evaluation Criteria
				AGP	Nergab	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Reslorton	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Xilica	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
99	Pregaballine	Capsule	75mg									
				Next Pharma	Reslorton	38	Qualified	14	80.58	5.7557	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Nergab	37	Qualified	14	214.84	15.346		Conformity with Bid Evaluation Criteria
				Pharmevo	Xilica	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Scirica	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Pegalin	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Zeegab	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Hilin	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
100	Pregaballine	Capsule	100mg									
				Next Pharma	Reslorton	38	Qualified	14	85.26	6.09	Lowest Evaluated	Conformity with Bid Evaluation Criteria

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				AGP	Nergab	37	Qualified	14	244.59	17.471		Conformity with Bid Evaluation Criteria
				Pharmevo	Xilica	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Zeegab	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Hilin	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
101	Trimetazidine	Tablet	35mg									
				Next Pharma	Trikat MR	35	Qualified	20	189.93	9.4965	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Servier	Vastarel MR	45	Qualified	20	320.55	16.028		Conformity with Bid Evaluation Criteria
102	Carbamazepin	Tablet	200mg									
				Paltinum	Seizunil	35	Qualified	50	204.85	4	Lowest Evaluated	Conformity with Bid Evaluation Criteria
103	Carbamazepin	Tablet	400mg	No Bid Received								
104	Clonazepam	Tablet	0.5mg	No Bid Received								
105	Clonazepam	Tablet	2mg	No Bid Received								
106	Clonazepam	Drops	0.25%	No Bid Received								
107	Flunarazine*	Capsule	5mg	No Bid Received								
108	Lacosamide*	Tablet	50mg									
				Hilton	Lacolep	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
109	Lacosamide*	Tablet	100mg									
				Hilton	Lacolep	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
110	Lacosamide*	Injection	10mg/ml	No Bid Received								
111	Levitracetam	Tablet	250mg									
				Helix	Eplipsa	37	Qualified	30	255	8.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Lumark	41	Qualified	30	748	24.933		Conformity with Bid Evaluation Criteria
				Pharmevo	Klevra	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Lerace	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Platinum	Levotam	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis	Lekra	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

112	Levitracetam	Tablet	500mg									
				Helix	Elipisa	37	Qualified	10	149	14.9	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Lumark	41	Qualified	30	1190.4	39.681		Conformity with Bid Evaluation Criteria
				Hilton	Lerace	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Platinum	Levotam	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Lekra	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
113	Levitracetam	Suspension	500mg									
				Hilton	Lerace	37	Qualified	1	112.63	112.63	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Lumark	41	Qualified	1	283.76	283.76		Conformity with Bid Evaluation Criteria
				Platinum	Levotam	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Lekra	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
114	Valporic Acid/ Sodium Valporate	Syrup	250mg									Non-Conformity with Bid Evaluation Criteria
				Platinum	Dapakan	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Divanza	17	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
115	Valporic Acid/ Sodium Valporate	Tablet	500mg									Non-Conformity with Bid Evaluation Criteria
				Platinum	Dapakan	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Divanza	17	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
116	Valporic Acid/ Sodium Valporate	Tablet	250mg									Non-Conformity with Bid Evaluation Criteria
				Platinum	Dapakan	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Divanza	17	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
117	Risperidone	Tablet	2mg									
				Helix Pharma	Recept	37	Qualified					Rate Not Quoted
				Hiranis Pharmaceutical	Zargus	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
118	Duloxetine	Capsule	30mg									
				The searle	Zenbar	37	Qualified	10	210.38	21.038	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Dulan	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
119	Escitalopram	Drops	10mg	No Bid Received								

[Handwritten mark]

[Handwritten mark]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

120	Escitalopram	Tablet	10mg									
				Hilton	Citanew	37	Qualified	14	119	8.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Morcet	41	Qualified	14	278.09	19.864		Conformity with Bid Evaluation Criteria
				AGP	Esi-dep	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Gleetal	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Estar	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Seradep	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
121	Fluoxetine	Tablet	20mg									
				Pharmatec	Oxetin	36	Qualified	14	88.9	6.35	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Flux	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
122	Levosulpride	Tablet	25mg									
				Helix Pharama	Lepride	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Scipride	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
123	Levosulpride	Tablet	50mg									
				Helix Pharama	Lepride	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Scipride	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
124	Paroxetine	Tablet	12.5mg									
				Helix Pharma	Pexot CR	38	Qualified	30	204	6.8	Lowest Evaluated	Conformity with Bid Evaluation Criteria
125	Paroxetine	Tablet	25mg									
				Helix Pharma	Pexot CR	37	Qualified	10	107	10.7	Lowest Evaluated	Conformity with Bid Evaluation Criteria
126	Sertraline	Tablet	50mg									
				Barrett Hodgson	Sert	40	Qualified	10	61.9	6.19	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmatec	Seroft	38	Qualified	30	151	5.0333		Conformity with Bid Evaluation Criteria
				Helix Pharma	Preloft	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
127	Procyclidine	Tablet	5mg	No Bid Received								
128	Ropinirole	Tablet	1mg	No Bid Received								
129	Atenolol	Tablet	25mg									

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Highnoon	Blokium	42	Qualified	30	69.86	2.3287	Lowest Evaluated	Conformity with Bid Evaluation Criteria
130	Atenolol	Tablet	50mg									
				Highnoon	Blokium	42	Qualified	30	153.9	5.13	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Atenorm	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
131	Atenolol	Tablet	100mg									
				Highnoon	Blokium	42	Qualified	20	101	5.05	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Atenorm	34	Disqualified					Non-Conformity with Bid Evaluation Criteria
132	Bisoprolol Fumarate	Tablet	2.5mg									
				Barrett Hodgson	Barilol	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
133	Bisoprolol Fumarate	Tablet	5mg									
				Barrett Hodgson	Barilol	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
134	Carvedilol	Tablet	6.25mg									
				Barrett Hodgson	Vedicar	35	Qualified	30	69.31	2.3103	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Carveda	40	Qualified	30	83.67	2.789		Conformity with Bid Evaluation Criteria
				Hilton	Carlov	26	Disqualified					Non-Conformity with Bid Evaluation Criteria
135	Labetalol	Injection	50mg	No Bid Received								
136	Labetalol	Tablet	100mg	No Bid Received								
137	Metoprolol Tartarate	Tablet	50mg	No Bid Received								
138	Metoprolol Tartarate	Tablet	100mg	No Bid Received								
139	Nebivolol	Tablet	2.5mg									
				The Searle	Byscard	41	Qualified	14	76.66	5.4757	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Highnoon	Nebix	42	Qualified	14	96.23	6.8736		Conformity with Bid Evaluation Criteria
				Pharmatec	Nebtec	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
140	Nebivolol	Tablet	5mg									
				Highnoon	Nebix	42	Qualified	14	113.2	8.0857	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Byscard	41	Qualified	14	127.3	9.0929		Conformity with Bid Evaluation Criteria
				Scilife	Nibovo	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Nebtec	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

141	Propranolol	Tablet	10mg	No Bid Received								
142	Propranolol	Tablet	40mg	No Bid Received								
143	Digoxin	Tablet	250µg	No Bid Received								
144	Glyceryl Trinitrate	Patch	5mg	No Bid Received								
145	Glyceryl Trinitrate	Injection	10mg	No Bid Received								
146	Glyceryl Trinitrate	Tablet	2.6mg									
				Maple Pharma	Glyrate	40	Qualified	30	99	3.3	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Sustac	42	Qualified	30	147.19	4.9063		Conformity with Bid Evaluation Criteria
147	Glyceryl Trinitrate	Tablet	6.4mg									
				Maple Pharma	Glyrate	41	Qualified	30	135	4.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The Searle	Sustac	42	Qualified	30	173.95	5.7983		Conformity with Bid Evaluation Criteria
148	Isosorbide 5-Mononitrate	Tablet	20mg	No Bid Received								
149	Ranolazine	Tablet	500mg									
				Maple Pharma	Ranzol XR	40	Qualified	14	186.06	13.29	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Highnoon	Ranola	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
150	Candesartan	Tablet	16mg									
				Pharmevo	Treatan	42	Qualified	28	140	5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
151	Candesartan + HCT	Tablet	16/12.5mg									
				Pharmevo	Treatan-D	42	Qualified	28	140	5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
152	Losartan Potassium	Tablet	50mg									
				Maple Pharma	Losan	38	Qualified	20	76	3.8	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Xavor	47	Qualified	10	42.56	4.256		Conformity with Bid Evaluation Criteria
				Pharmevo	Tansin	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Losmart	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Giozar	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Sartan	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

153	Losartan Potassium + HCT	Tablet	50/12.5mg									
				FerozSons	Xavor DIU	46	Qualified	10	43.87	4.387	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Maple Pharma	Losan-H	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Tansin Diu	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Giozar D	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Sartan-H	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
154	Telmisartan + Amlodipine*	Tablet	40/5mg									
				Pharmevo	Telsarta-A	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Am Telsan	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
155	Telmisartan*	Tablet	20mg									
				Highnoon	Misar	42	Qualified	14	85.68	6.12	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Telsan	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
156	Telmisartan*	Tablet	40mg									
				Highnoon	Misar	42	Qualified	14	114.6	8.1857	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmevo	Telsarta	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Telsan	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
157	Valsartan + Amlodipine + HCT	Tablet	10/160/12.5 mg									
				Highnoon	Triforge	42	Qualified	28	308	11	Lowest Evaluated	Conformity with Bid Evaluation Criteria
158	Valsartan+Hydrochlorthiazide*	Tablet	80/12.5mg				Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
159	Valsartan+Hydrochlorthiazide*	Tablet	160/12.5mg				Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
160	Amlodipine	Tablet	5mg									
				Barrett Hodgson	Ampress	35	Qualified	20	36.8	1.84	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmatec	Amlocard	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	AmloNext	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	M-Low	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
161	Amlodipine	Tablet	10mg									
				Pharmatec	Amlocard	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	AmloNext	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

162	Amlodipine + Valsartan	Tablet	5/160mg									
				Pharmevo	Avsar Plus	39	Qualified	14	121	8.6429	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Extore	42	Qualified	14	278.46	19.89		Conformity with Bid Evaluation Criteria
				Highnoon	Biforge	38	Qualified	14	123.2	8.8		Conformity with Bid Evaluation Criteria
				AGP	Exotan	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Valmo	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Ferozsons	Covance	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Helix Pharma	Valsar - M	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Valvit AM	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Amstan	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Diasar	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	AV-Sartan	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
163	Amlodipine + Valsartan	Tablet	5/80mg									
				Highnoon	Biforge	38	Qualified	14	95.76	6.84	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Extor	42	Qualified	14	222.77	15.912		Conformity with Bid Evaluation Criteria
				Pharmevo	Avsar Plus	39	Qualified	14	105	7.5		Conformity with Bid Evaluation Criteria
				AGP	Exotan	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Valmo	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Ferozsons	Covance	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Helix Pharma	Valsar - M	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Valvit AM	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Amstan	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Diasar	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	AV-Sartan	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
164	Amlodipine + Valsartan	Tablet	10/160mg									
				Scilife	Amstan	35	Qualified	28	178.43	6.3725	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Extor	42	Qualified	14	331.5	23.679		Conformity with Bid Evaluation Criteria
				Pharmevo	Avsar Plus	39	Qualified	14	143.5	10.25		Conformity with Bid Evaluation Criteria
				Highnoon	Biforge	38	Qualified	14	126.6	9.0429		Conformity with Bid Evaluation Criteria
				AGP	Exotan	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Valmo	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Ferozsons	Covance	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Ferozsons	Clopid	45	Qualified	10	71.95	7.195		Conformity with Bid Evaluation Criteria	
				Scilife	Norplate	39	Qualified	28	121.74	4.3479		Conformity with Bid Evaluation Criteria	
				Bosch Pharma	Ogrel	36	Qualified	10	126.88	12.688		Conformity with Bid Evaluation Criteria	
				Highnoon	Pidogrel	38	Qualified	10	60.3	6.03		Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Clotnil	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
178	Clopidogrel+Aspirin	Tablet	75/75mg										
				Highnoon	Pidogrel AP	39	Qualified	10	67.16	6.716	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Bosch Pharma	Ogrel Plus	39	Qualified	10	130.61	13.061		Conformity with Bid Evaluation Criteria	
				Pharmevo	Lowplate Plus	42	Qualified	10	79	7.9		Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Clotnil Plus	25	Disqualified					Non-Conformity with Bid Evaluation Criteria	
179	Enoxaparin	Injection	60mg										
				Sanofi Aventis	Clexane	45	Qualified	2	1091.1	545.56	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
180	Enoxaparin	Injection	80mg			0							
181	Rivaroxaban*	Tablet	10mg			0							
				Highnoon	Rivaro	37	Qualified	10	80.33	8.033	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				The Searle	Xaroban	36	Qualified	10	200	20		Conformity with Bid Evaluation Criteria	
				Pharmevo	Xcept	42	Qualified	10	85	8.5		Conformity with Bid Evaluation Criteria	
				Bayer Pakistan	Xarelto	46	Qualified	5	1231.4	246.29		Conformity with Bid Evaluation Criteria	
				Next Pharma	Verinoxa	25	Disqualified					Non-Conformity with Bid Evaluation Criteria	
182	Tranexamic Acid	Injection	500mg										
				Hilton	Transamin	37	Qualified	10	897.76	89.776	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				AGP	Maxna	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
183	Warfarin	Tablet	5mg	No Bid Received									
184	Atorvastatin	Tablet	10mg										
				Highnoon	Lipirex	43	Qualified	10	32.18	3.218	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Getz	Lipiget	47	Qualified	10	46	4.6		Conformity with Bid Evaluation Criteria	
				Maple Pharma	Lipotrim	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Macter	Tavist	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Scilife	Lochol	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Barrett Hodgson	Sensicon	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
185	Atorvastatin	Tablet	20mg										
				Scilife	Lochol	36	Qualified	30	80	2.6667		Conformity with Bid Evaluation Criteria	
				Highnoon	Lipirex	43	Qualified	10	48.15	4.815		Conformity with Bid Evaluation Criteria	
				Getz	Lipiget	47	Qualified	10	70	7		Conformity with Bid Evaluation Criteria	
				Maple Pharma	Lipotrim	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Macter	Tavist	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Sensicon	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
186	Fenofibrate	Tablet	67mg	No Bid Received									
187	Rosuvastatin	Tablet	10mg										
				Scilife	Kestore	39	Qualified	10	43.64	4.364	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Pharmevo	Xplended	39	Qualified	10	89	8.9		Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Rosubar	39	Qualified	10	62.4	6.24		Conformity with Bid Evaluation Criteria	
				The Searle	Vaptor	40	Qualified	10	150	15		Conformity with Bid Evaluation Criteria	
				Getz	Rovista	47	Qualified	10	75	7.5		Conformity with Bid Evaluation Criteria	
				FerozSons	Aurora	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Next Pharma	Rosunext	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Maple Pharma	Rostin	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Macter	omnitor	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Shaigan	Xell	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Hilton	Rolip	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Highnoon	Rosulin	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
				Hiranis Pharmaceutical	Rosuvast	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
188	Rosuvastatin	Tablet	20mg										
				Pharmevo	Xplended	39	Qualified	10	200	20	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Scilife	Kestore	39	Qualified	10	60.28	6.028	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Highnoon	Rosulin	41	Qualified	10	120.5	12.05		Conformity with Bid Evaluation Criteria	
				Barrett Hodgson	Rosubar	43	Qualified	10	87.4	8.74		Conformity with Bid Evaluation Criteria	
				The Searle	Vaptor	40	Qualified	10	300	30		Conformity with Bid Evaluation Criteria	
				Getz	Rovista	47	Qualified	10	160	16		Conformity with Bid Evaluation Criteria	

[Handwritten mark]

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				FerozSons	Aurora	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Helix Pharma	Loster	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Rosunext	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Maple Pharma	Rostin	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Macter	omnitor	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Rosuvast	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
189	Alpha Methyl dopa	Tablet	250mg	No Bid Received								
190	Oxybutynin (HCl)	Tablet	5mg	No Bid Received								
191	Tamsulosin	Tablet	0.4mg									
				Highnoon	Prostam	40	Qualified	28	246	8.7857	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Getz	Tamsolin	41	Qualified	20	202	10.1		Conformity with Bid Evaluation Criteria
				FerozSons	Flosure	39	Qualified	20	190.75	9.5375		Conformity with Bid Evaluation Criteria
				Next Pharma	Tamlin MR	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
192	Fenticonazole	Cream	2%	No Bid Received								
193	Fluconazole	Capsule	150mg									
				Platinum	Fungix	41	Qualified	1	80.75	80.75	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Helix Pharma	Fugix	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Logican	16	Disqualified	-	-	-		
194	Itraconazole*	Capsule	100mg			0						
				FerozSons	Icon	41	Qualified	4	98.8	24.7	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Tolsura	17	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
195	Nystatin	Drops	100000IU	No Bid Received								
196	Terbinafine	Tablet	125mg									
				Hiranis Pharmaceutical	Caweda	17	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
197	Terbinafine	Tablet	250mg									
				Hiranis Pharmaceutical	Caweda	17	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
198	Rifaximin*	Tablet	550mg									

[Handwritten mark]

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				FerozSons	Rifaxa	47	Qualified	10	469	46.9	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Zerifax	36	Qualified	10	573.24	57.324		Conformity with Bid Evaluation Criteria
				Kaizen	Orifax	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
199	Artemether + Lumefantrine	Suspension	15/90mg									
				Platinum	Hiservin	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
200	Acyclovir	Tablet	200mg									
				FerozSons	Acylex	39	Qualified	25	251.18	10.047	Lowest Evaluated	Conformity with Bid Evaluation Criteria
201	Acyclovir	Cream		No Bid Received								
202	Acyclovir	Suspension	200mg	No Bid Received								
203	Amoxicillin	Capsule	500mg	No Bid Received								
204	Amoxicillin	Suspension	125mg	No Bid Received								
205	Amoxicillin + Clavulanic Acid	Injection	1.2gm									
				Bosch Pharma	Calamox	47	Qualified	1	178	178	Lowest Evaluated	Conformity with Bid Evaluation Criteria
206	Amoxicillin + Clavulanic Acid	Tablet	375mg	No Bid Received								
207	Amoxicillin + Clavulanic Acid	Tablet	625mg	No Bid Received								
				Bosch Pharma	Calamox	47	Qualified	6	113.94	18.99	Lowest Evaluated	Conformity with Bid Evaluation Criteria
208	Amoxicillin + Clavulanic Acid	Tablet	1gm									
				Bosch Pharma	Calamox	47	Qualified	6	149.69	24.948	Lowest Evaluated	Conformity with Bid Evaluation Criteria
209	Amoxicillin + Clavulanic Acid	Suspension	156.25mg									
				Macter	Co-Amoxi	35	Qualified	1	84	84	Lowest Evaluated	Conformity with Bid Evaluation Criteria
210	Amoxicillin + Clavulanic Acid	Suspension	312.5mg			0						
				Macter	Co-Amoxi	35	Qualified	1	120	120	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bosch Pharma	Calamox	47	Qualified	1	130.25	130.25		Conformity with Bid Evaluation Criteria
211	Meropenam*	Injection	500mg									
				Bosch Pharma	Penro	47	Qualified	1	839.45	839.45	Lowest Evaluated	Conformity with Bid Evaluation Criteria
212	Meropenam*	Injection	1gm	No Bid Received								
213	Pipracillin + Tazobactam	Injection	2.25gm									

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Bosch Pharma	Tanzo	47	Qualified	1	375.74	375.74	Lowest Evaluated	Conformity with Bid Evaluation Criteria
214	Pipracillin + Tazobactam	Injection	4.5gm									
				Bosch Pharma	Tanzo	47	Qualified	1	722.27	722.27	Lowest Evaluated	Conformity with Bid Evaluation Criteria
215	Doxycycline	Capsule	100mg									
				Platinum	Nordox	39	Qualified	30	152.32	5.0773	Lowest Evaluated	Conformity with Bid Evaluation Criteria
216	Cefaclor	Drops	50mg									
				AGP	Ceclor	43	Qualified	1	155.58	155.58	Lowest Evaluated	Conformity with Bid Evaluation Criteria
217	Cefaclor	Suspension	125mg									
				AGP	Ceclor	45	Qualified	1	241.97	241.97	Lowest Evaluated	Conformity with Bid Evaluation Criteria
218	Cefaclor	Suspension	250mg									
				AGP	Ceclor	45	Qualified	1	422.97	422.97	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Cavalor	34	Disqualified					Non-Conformity with Bid Evaluation Criteria
219	Cefixime	Capsule	400mg									
				Bosch Pharma	Cebosh	36	Qualified	5	276.15	55.23	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Cinklare	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Evofix	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Cefim	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Ceflorex	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Cefia	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Platinum	Ceftas	15	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
220	Cefixime	Suspension	200mg									
				Bosch Pharma	Cebosh	37	Qualified	1	210.14	210.14	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Highnoon	Cefia DS	38	Qualified	1	228.7			Conformity with Bid Evaluation Criteria
				AGP	Cinklare	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Evofix Ds	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Ruwin DS	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Cefim DS	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Ceflorex DS	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Platinum	Ceftas	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

221	Cefixime	Suspension	100mg									
				Bosch Pharma	Cebosh	36	Qualified	1	154.64	154.64	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Cinklare	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Ruwin	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Cefim	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Ceflorex	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Platinum	Ceftas	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
222	Cefoperazone + Sulbactam	Injection	2gm									
				Shaigan	Deezon Plus	36	Qualified	1	161.08	161.08	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bosch Pharma	Cebac	37	Qualified	1	297.37	297.37		Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Ceflactam	40	Qualified	1	188.44	188.44		Conformity with Bid Evaluation Criteria
				Highnoon	Xorvact	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
223	Cefotaxime	Injection	500mg									
				Sanof Aventis	Clafon	44	Qualified	1	127.23	127.23	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Wintax	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
224	Cefotaxime	Injection	1gm									
				Sanof Aventis	Clafon	44	Qualified	1	211.15	211.15	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Shaigan	Cilver 1000	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Wintax	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
225	Ceftriaxone	Injection	500mg									
				Bosch Pharma	Cefxone	38	Qualified	1	164.2	164.2	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Neogene	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Cefro	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
226	Ceftriaxone	Injection	1gm									
				Bosch Pharma	Cefxone	39	Qualified	1	244.9	244.9	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Neogene	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Celtis	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Cefro	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
227	Cephradine	Suspension	125mg	No Bid Received								

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

228	Ciprofloxacin	Tablet	250mg									
				Highnoon	Cyrocin	43	Qualified	10	68.85	6.885	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bayer pakistan	Ciproxin	46	Qualified	10	235.29	23.529		Conformity with Bid Evaluation Criteria
				FerozSons	Proflox	39	Qualified	10	85.9	8.59		Conformity with Bid Evaluation Criteria
				AGP	Algocin	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				The searle	Cinoxin	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Alacep	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Hiflox	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Kvin	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Zolina	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
229	Ciprofloxacin	Tablet	500mg									
				Highnoon	Cyrocin	43	Qualified	10	111.9	11.19	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bayer pakistan	Ciproxin	46	Qualified	10	414.12	41.412		Conformity with Bid Evaluation Criteria
				FerozSons	Proflox	37	Qualified	10	156.17	15.617		Conformity with Bid Evaluation Criteria
				AGP	Algocin	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				The searle	Cinoxin	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Alacep	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Hiflox	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	kvin	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Zolina	24	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
230	Ciprofloxacin	Suspension	200mg									
				Bosch Pharma	Quinoflox	37	Qualified	1	130.61	130.61	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Cinoxin	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
231	Levofloxacin	Tablet	500mg									
				Getz	Leflox	47	Qualified	10	129	12.9	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Levo	37	Qualified	10	157.36	15.736		Conformity with Bid Evaluation Criteria
				Pharmatec	Leflotec	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				The searle	Levoxin	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Bexus	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				PDH	Quest	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Voxiquin	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Olevo	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Dynaquin	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
232	Levofloxacin	Infusion	500mg									
				The searle	Levoxin	37	Qualified	10	211.23	21.123	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Dynaquin	30	Disqualified					Non-Conformity with Bid Evaluation Criteria
233	Levofloxacin	Tablet	250mg									
				Highnoon	Voxiquin	37	Qualified	10	62.78	6.278	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Getz	Leflox	47	Qualified	10	72	7.2		Conformity with Bid Evaluation Criteria
				FerozSons	Levo	37	Qualified	10	96.04	9.604		Conformity with Bid Evaluation Criteria
				The searle	Levoxin	37	Qualified	10	136.85	13.685		Conformity with Bid Evaluation Criteria
				Pharmatec	Leflotec	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Quest	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Olevo	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Dynaquin	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
234	Moxifloxacin	Infusion	400mg									
				The searle	Maxlox	36	Qualified	1	250	250	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bayer pakistan	Avelox	45	Qualified	1	1370.8	1370.8		Conformity with Bid Evaluation Criteria
				Highnoon	Oxaquin	35	Qualified	1				Rate Not Quoted
				Bosch Pharma	Izilon	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Xefecta	23	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
235	Moxifloxacin	Tablet	400mg									
				The searle	Maxlox	36	Qualified	5	242.25	48.45	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bayer pakistan	Avelox	45	Qualified	5	841.82	168.36		Conformity with Bid Evaluation Criteria
				Scilife	Scimox	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Xefecta	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Hiramox	19	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Barimox	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

236	Amikacin Sulphate	Injection	100mg	No Bid Received								
237	Amikacin Sulphate	Injection	250mg	No Bid Received								
238	Amikacin Sulphate	Injection	500mg									
				Bosch Pharma	Amkay	47	Qualified	1	128.07	128.07	Lowest Evaluated	Conformity with Bid Evaluation Criteria
239	Azithromycin	Tablet	250mg									
				Highnoon	Azipos	36	Qualified	10	189.3	18.93	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Bosch Pharma	Zezot	42	Qualified	6	123.08	20.513		Conformity with Bid Evaluation Criteria
				The searle	Virdi	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				FerozSons	Azobar	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Trezo	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Kaizen	Servaz	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Atizor	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
240	Azithromycin	Tablet	500mg									
				Bosch Pharma	Zezot	42	Qualified					Rate Not Quoted
				FerozSons	Azobar	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Kaizen	Servaz	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Atizor	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
241	Clarithromycin	Tablet	250mg	No Bid Received								
242	Clarithromycin	Tablet	500mg	No Bid Received								
243	Fosfomycin	Sachet		No Bid Received								
244	Gentamicin	Injection	40mg	No Bid Received								
245	Lincomycin	Capsule	500mg									
				Hiranis Pharmaceutical	Locomin	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
246	Miconazole (Nitrate)	Gel	2%	No Bid Received								
247	Triamcinolone Oral Base	Gel		No Bid Received								
248	Clotrimazole	Cream	2%									
				Platinum	Oligyn V	39	Qualified	1	79.69	79.69	Lowest Evaluated	Conformity with Bid Evaluation Criteria

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

249	Dydrogesterone*	Tablet	10mg									
250	Ethinylestradiol+Drospire non*	Tablet	0.02/3mg									
				Bayer pakistan	YAZ	46	Qualified	28	683.72	24.419	Lowest Evaluated	Conformity with Bid Evaluation Criteria
251	Miconazole Vaginal	Cream	2%	No Bid Received								
252	Oxytocin	Injection	10IU	No Bid Received								
253	Beclomethasone Dipropionate	Inhalers	250mcg									
				Chiesi	Clenil	50	Qualified	1	473.12	473.12	Lowest Evaluated	Conformity with Bid Evaluation Criteria
254	Beclomethasone Dipropionate	Nebules	0.8mg/2ml									
				Chiesi	Clenil aerosol Nebulising Suspension	50	Qualified	10	760.41	76.041	Lowest Evaluated	Conformity with Bid Evaluation Criteria
255	Beclomethasone + Formoterol Dipropionate	Inhalers	100/6µg									Conformity with Bid Evaluation Criteria
				Chiesi	Foster PMDI	50	Qualified	1	1031.3	1031.3	Lowest Evaluated	
256	Beclomethasone + Salbutamol	Inhalers	250/100µg	No Bid Received								
257	Doxofylline*	Tablet	400mg									
				Kaizen	Profyline	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Agolix	18	Disqualified	-	-	-		
258	Doxofylline*	Syrup	100mg									
				Kaizen	Profyline	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Agolix	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
259	Fluticasone Propionate*	Inhalers	250µg									
260	Ipratropium Bromide	Nebules	500mcg/2ml	Chiesi	Atem	50	Qualified	10	746.94	74.694	Lowest Evaluated	Conformity with Bid Evaluation Criteria
261	Montelukast	Tablet	5mg									
				Hilton	Myteka	37	Qualified	14	155.13	11.081	Lowest Evaluated	Conformity with Bid Evaluation Criteria

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Scilife	Asthivin	35	Qualified	-	-	-		Rate Not Quoted
				AGP	Lucast	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Montec	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Montana	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Aerokast	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
262	Montelukast	Tablet	10mg									
				Hilton	Myteka	37	Qualified	14	170	12.143	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				The searle	Ventek	42	Qualified	14	200	14.286		Conformity with Bid Evaluation Criteria
				AGP	Lucast	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Montec	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	Airmont	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Aireez	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				PDH	Montana	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Aerokast	27	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
263	Paracetamol ,Pseudoephedrine Chlorphenaramine	Tablet		No Bid Received								
264	Paracetamol + Pseudoephedrine + Triprolidine	Elixer		No Bid Received								
265	Paracetamol + Pseudoephedrine + Triprolidine	Tablet		No Bid Received								
266	Salbutamol	Tablet	2mg									
				Pharmatec	Venex	37	Qualified	20	22.6	1.13	Lowest Evaluated	Conformity with Bid Evaluation Criteria
267	Salbutamol	Inhalers	100µg									
				Macter	Inspiro	35	Qualified	1	170	170	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Platinum	Salbest	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
268	Salbutamol	Syrup	2mg									
				Pharmatec	Venex	37	Qualified	1	48.5	48.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				PDH	Butamin	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
269	Salmeterol, Fluticasone Propionate	Inhalers	25/250µg									
				Macter	Salmicort INH	35	Qualified	1	590	590	Lowest Evaluated	Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

270	Terbutaline	Syrup	0.3mg										
				Barrett Hodgson	Britanyl	35	Qualified	1	31.5	31.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
271	Diphenhydramine+ Dextromethorphan + Ephedrine + Guaphenesin	Syrup		No Bid Received									
272	Dextromethorphan	Syrup		No Bid Received									
273	Acephylline	Syrup		No Bid Received									
274	Acephylline, Diphenhydramine	Syrup											
275	Ammonium Chloride+Chlorphenirami ne malaete+phenylephrine HCl	Syrup											
				Pharmatec	Reltus Exp	43	Qualified	1	42.38	42.38	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
276	Diphenhydramine, Aminophylline, Ammonium Chloride, Menthol	Syrup		No Bid Received									
				The searle	Hydrilin	42	Qualified	1	51.61	51.61	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				PDH	Vindril	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
277	Glibenclamide	Tablet	5mg	No Bid Received									
278	Gliclazide	Tablet	30mg										
				Next Pharma	GliNext MR	36	Qualified	30	189.3	6.31	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				FerozSons	Diabetron CR	39	Qualified	30	190.5	6.35		Conformity with Bid Evaluation Criteria	
				Servier	Diamicron MR	43	Qualified	20	247.85	12.393		Conformity with Bid Evaluation Criteria	
279	Gliclazide	Tablet	60mg										
				FerozSons	Diabetron FZS	35	Qualified	30	236.7	7.89	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Servier	Diamicron MR	42	Qualified	20	355.99	17.8		Conformity with Bid Evaluation Criteria	
				Scilife	Scicon MR	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria	
280	Glimepiride	Tablet	2mg										
				Barrett Hodgson	Diabold	35	Qualified	20	36.28	1.814	Lowest Evaluated	Conformity with Bid Evaluation Criteria	
				Getz	Getryl	47	Qualified	30	55	1.8333		Conformity with Bid Evaluation Criteria	
				Pharmevo	Evopride	37	Qualified	30	59	1.9667		Conformity with Bid Evaluation Criteria	

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				AGP	Gluconorm	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Maple Pharma	Glyper	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
281	Glimepiride	Tablet	4mg									
				Pharvevo*	Evopride	36	Qualified	30	78	2.6	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Getz*	Getryl	47	Qualified	30	80	2.6667	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Gluconorm	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Maple Pharma	Glyper	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Diabold	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
282	Insulin 70/30	Injection	100IU									
				Novo nordisk	Mixtard-30	49	Qualified	1	430	430	Lowest Evaluated	Conformity with Bid Evaluation Criteria
283	Insulin N	Injection	100IU									
				Novo nordisk	Insulatard	49	Qualified	1	430	430	Lowest Evaluated	Conformity with Bid Evaluation Criteria
284	Insulin R	Injection	100IU									
				Novo nordisk	Actrapid	49	Qualified	1	430	430	Lowest Evaluated	Conformity with Bid Evaluation Criteria
285	Metformin	Tablet	500mg	No Bid Received								
286	Metformin	Tablet	1gm	No Bid Received								
287	Metformin, Glimipride	Tablet	1/500mg									
				AGP	Gluconormet	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
288	Metformin, Glimipride	Tablet	2/500mg									
				Shaigan	Dilgem plus	35	Qualified	20	52.97	2.6485	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Gluconormet	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
289	Pioglitazone	Tablet	15mg			0						
				AGP	Poze	40	Qualified	14	106.24	7.5886	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Piozer	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
290	Pioglitazone + Metformin	Tablet	15/500mg									
				AGP	Pozemet	41	Qualified	14	87.01	6.215	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Piozer Plus	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
291	Sitagliptin	Tablet	50mg									

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Highnoon	Tagip	37	Qualified	14	116.6	8.3286	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Glyzia	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Galsit	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				FerozSons	Sitagen	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Inosita	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Glusit	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Sitaglu	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	S-Gliptin	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
292	Sitagliptin + Metformin	Tablet	50/500mg									
				Getz	Treviamet	47	Qualified	14	160	11.429	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Sitagen-M	38	Qualified	30	352.67	11.756		Conformity with Bid Evaluation Criteria
				The searle	JentinMet	38	Qualified	14	268.52	19.18		Conformity with Bid Evaluation Criteria
				Highnoon	Tagipmet	43	Qualified	14	169.6	12.114		Conformity with Bid Evaluation Criteria
				AGP	Glyziamet	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Galsitmet	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Helix Pharma	Juvia-M Plus	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	SitaNext	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Inosita Plus	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Glusimet	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Shaigan	Admit	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Sitaglumet	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	S-Gliptin Plus	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
293	Sitagliptin + Metformin	Tablet	50/1000mg									
				Highnoon	Tagipmet	43	Qualified	14	180.8	12.914	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Sitagen-M	37	Qualified	10	196.97	19.697		Conformity with Bid Evaluation Criteria
				The searle	JentinMet	36	Qualified	14	317.15	22.654		Conformity with Bid Evaluation Criteria
				Getz	Treviamet	47	Qualified	14	195	13.929		Conformity with Bid Evaluation Criteria
				Pharmatec	Galsitmet	26	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Helix Pharma	Juvia-M Plus	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmevo	Inosita Plus	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Next Pharma	SitaNext	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Scilife	Glusimet	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten mark]

[Handwritten signature]
[Handwritten signature]
[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				Shaigan	Admit	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Hilton	Sitagliumet	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Barrett Hodgson	S-Gliptin Plus	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
294	Sitagliptin + Metformin	Tablet	50/850mg									
				FerozSons	Sitagen-M	40	Qualified	14	240.27	17.162	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Sitagliumet	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
295	Vildagliptin + Metformin	Tablet	50/850mg									
				Pharmevo	Galvecta plus	35	Qualified	14	180	12.857	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				FerozSons	Valiant-M	35	Qualified	10	153	15.3		Conformity with Bid Evaluation Criteria
296	Vildagliptin + Metformin	Tablet	50/500mg									
				FerozSons	Valiant-M	40	Qualified					Rate Not Quoted
				Pharmevo	Galvecta plus	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
297	Vildagliptin + Metformin	Tablet	50/1000mg									
				FerozSons	Valiant-M	40	Qualified	10	165	16.5	Lowest Evaluated	Conformity with Bid Evaluation Criteria
298	Thyroxine	Tablet	100µg	No Bid Received								
299	Alfa Calcidol	Tablet	0.5µg									
				Platinum	Alfa D	40	Qualified	10	156.4	15.64	Lowest Evaluated	Conformity with Bid Evaluation Criteria
300	B-Complex, Lysine, Vit C	Syrup		No Bid Received								
301	Calcium Carbonate + Vit D	Tablet										
				PDH	Calcium P	39	Qualified	30	70	2.3333	Lowest Evaluated	Conformity with Bid Evaluation Criteria
302	Calcium*	Tablet		No Bid Received								
303	Cholicalciferol	Injection	5mg									
				Pharmatec	Choltec	35	Qualified	1	55	55	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmevo	OPT-D	32	Disqualified	-	-	-		
304	Cholicalciferol	Drops	400IU									
				Hiranis Pharmaceutical	Min D	25	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

305	Folic Acid	Tablet	5mg	No Bid Received								
307	Iron + Folic Acid	Tablet	100+0.35mg									
				AGP	Ribifer-F Chewable	38	Qualified	20	199.13	9.9565	Lowest Evaluated	Conformity with Bid Evaluation Criteria
308	Iron Polymaltose	Tablet										
			100mg									
				AGP	Rubifer	40	Qualified	20	181.52	9.076	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Ferosoft	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
309	Iron Polymaltose	Syrup	50mg/5ml									
				AGP	Rubifer	40	Qualified	1	180.88	180.88	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Ferosoft	34	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
310	Iron Polymaltose + Folic Acid	Syrup		No Bid Received								
311	Iron Sucrose	Injection	100mg/5ml									
				Boch Pharma	Merofer	42	Qualified	25	940.39	37.616	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Rubiject	39	Qualified	5	979.62	195.92		Conformity with Bid Evaluation Criteria
				Shaigan	Irose	37	Qualified	5	318.92	63.784		Conformity with Bid Evaluation Criteria
312	Mecobalamine	Injection	500µg									
				Hilton	Methycobal	37	Qualified	10	1058.9	##	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Mecovate	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Mecotec	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
313	Mecobalamine	Tablet	500µg									
				Hilton	Methycobal	37	Qualified	100	1656.1	16.561	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Mecovate	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Pharmatec	Mecotec	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
314	Multivitamin + Minerals	Tablet	10mg									
				The searle	Vitrum	42	Qualified	30	203.32	6.7773	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Supravit M	37	Qualified	30	571.2	19.04		Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Vit & Min Heart	18	Disqualified					Non-Conformity with Bid Evaluation Criteria

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

315	Multivitamin + Minerals	Syrup		No Bid Received								
316	Pizotifin+Vit.B Complex*	Syrup		No Bid Received								
317	Vitamin C*	Tablet	500mg	No Bid Received								
318	Vitamin E	Capsule	200mg	No Bid Received								
319	Vitamin E	Capsule	400mg	No Bid Received								
320	Vitamin E	Capsule	600mg	No Bid Received								
321	Vitamin E, Zinc, Vitamin B Complex,Folic Acid	Capsule		No Bid Received								
322	Vitamins + Iron	Syrup		No Bid Received								
323	Betamethasone	Tablet	0.5mg	No Bid Received								
324	Dexamethasone	Injection	4mg	No Bid Received								
325	Ethinylestradiol+ Cyroterone acetate	Tablet		No Bid Received								
326	Hydrocortisone	Injection	100mg	No Bid Received								
327	Hydrocortisone	Injection	250mg	No Bid Received								
328	Hydrocortisone	Injection	500mg	No Bid Received								
329	Norethisterone	Tablet	5mg									
				Bayer Pakistan	Primolut N	46	Qualified	30	230.67	7.689	Lowest Evaluated	Conformity with Bid Evaluation Criteria
330	Prednisolone*	EC Tablet	5mg	No Bid Received								
331	Prednisolone*	Tablet	5mg	No Bid Received								
				Hiranis Pharmaceutical	Inflagic	18	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
332	Prednisolone*	Liquid	5mg	No Bid Received								
333	Adaplene	Cream	0.1%	No Bid Received								
334	Bacitracin + Neomycin	Cream	15Grm	No Bid Received								

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

335	Bacitracin + Polymyxin	Ointment	15Grm	No Bid Received								
336	Bacitracin, Lignocain, Polymyxin, Neomycin	Ointment		No Bid Received								
337	Betamethasone + Neomycin	Lotion	ml	No Bid Received								
338	Betamethasone + Neomycin	Ointment	15Grm	No Bid Received								
339	Betamethasone + Neomycin	Cream	15Grm	No Bid Received								
340	Betamethasone + Neomycin + Miconazole	Cream	15Grm	No Bid Received								
341	Betamethasone Topical	Cream	0.05%	No Bid Received								
342	Betamethasone Topical	Ointment	0.05%	No Bid Received								
343	Betamethasone, Gentamicin	Cream	0.05/0.1%									
				Hiranis Pharmaceutical	Gen-beta	18	Disqualified					Non-Conformity with Bid Evaluation Criteria
344	Betamethasone, Salicylic Acid	Ointment	15	No Bid Received								
345	Clindamycin	Gel	1%	No Bid Received								
346	Clobetasol	Ointment	0.05%	No Bid Received								
347	Clobetasol	Cream	0.05%	No Bid Received								
348	Clobetasol+ Nystatin + Neomycin	Ointment		No Bid Received								
349	Crotamiton + Sulphar	Cream		No Bid Received								
350	Crotamiton + Sulphar	Lotion		No Bid Received								
351	Fusidic Acid	Cream	2%									
				Platinum	Infacid	39	Qualified	1	77.78	77.78	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Hifuzin	21	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
352	Fusidic Acid, Hydrocortisone	Cream										
				Hiranis	Hifuzin HC	21	Disqualified	-	-	-		
353	Hydrocortisone Topical	Cream	1%				Not Quoted					

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

354	Hydrocortisone+ Clotrimazole*	Cream	1%				Not Quoted						
				Hiranis Pharmaceutical	Defungo	18	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
355	Ivermectin	Tablet	6mg	No Bid Received									
356	Silver Sulphadiazine	Cream	1%	No Bid Received									
357	Triamcinolone Topical	Ointment	0.1%	No Bid Received									
358	Triamcinolone, Neomycin, Gramicidin, Nystatin	Cream		No Bid Received									
359	Fenticonazole	Cream	2%	No Bid Received									
360	Terbinafine (HCl)	Gel	1%	No Bid Received									
361	Permethrin 5%	Cream											
				Shaigan	Skab Cream	33	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
				Hiranis Pharmaceutical	Plaveo	18	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
362	Ciprofloxacin + Lignocain Ear Drops	Ear Drops	0.3 % + 5%	Barrett Hodgson	Cipocain	35	Qualified	1	61.2	61.2	Lowest Evaluated		Conformity with Bid Evaluation Criteria
				Sante	Zeprocaine	34	Disqualified						Non-Conformity with Bid Evaluation Criteria
363	Ciprofloxacin, Dexamethasone	Ear Drops	0.30%+0.1%										
				Barrett Hodgson	Cipotlc D	35	Qualified	1	68.85	68.85	Lowest Evaluated		Conformity with Bid Evaluation Criteria
				Sante	Zeprodex	34	Disqualified	-	-	-			Non-Conformity with Bid Evaluation Criteria
364	Clotrimazole*	Solution	1%	No Bid Received									
365	Fluticasone Nasal Spray	Nasal Spray		No Bid Received									
366	Mometasone Furoate	Nasal Spray		No Bid Received									
			0.0005	Sante	Nasomet	35	Qualified	1	521.86	521.86	Lowest Evaluated		Conformity with Bid Evaluation Criteria
367	Ofloxacin Ear Drops	Ear Drops	0.6%										
				Sante	Otoflox	35	Qualified	1	92.83	92.83	Lowest Evaluated		Conformity with Bid Evaluation Criteria
368	Ofloxacin Ear Drops	Ear Drops	0.3%										
				Sante	Otoflox	35	Qualified	1	67	67	Lowest Evaluated		Conformity with Bid Evaluation Criteria
369	Polymyxin, Neomycin	Ear Drops		No Bid Received									
370	Saline Nasal Drops*	Nasal Drops		No Bid Received									
371	Triamcinolone Nasal Spray	Nasal Spray		No Bid Received									
372	Xylometazoline	Nasal Spray	0.1%	No Bid Received									

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

373	Betoxolol	Eye Drops	0.5%	No Bid Received								
374	Brimonidine Ophthalmic Solution	Eye Drops	0.2%	Sante	Brimonidine Ophthalmic Solution	35	Qualified	1	210.59	210.59	Lowest Evaluated	Conformity with Bid Evaluation Criteria
375	Dorzolamide	Eye Drops	2%	No Bid Received								
376	Dorzolamide + Timolol	Eye Drops	2/0.5%									
				Helix Pharma	Hisopt	38	Qualified	1	205	205	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Sante	Co-Dorzal	35	Qualified	1	649.15	649.15		Conformity with Bid Evaluation Criteria
377	Latanoprost	Eye Drops	0.005%	No Bid Received								
378	Levobunolol	Eye Drops	0.5%									
				Barrett Hodgson	Betabar	35	Qualified	1	130.9	130.9	Lowest Evaluated	Conformity with Bid Evaluation Criteria
379	Travoprost*	Eye Drops	0.0041%									
380	Chloramphenicol	Eye Drops	0.5%									
				Sante	Santochlor	35	Qualified	1	71.96	71.96	Lowest Evaluated	Conformity with Bid Evaluation Criteria
381	Gentamycin E/D*	Eye Drops	0.3%	No Bid Received								
382	Levofloxacin Eye Drops	Eye Drops	0.5%	No Bid Received								
383	Moxifloxacin Eye Drops	Eye Drops	0.5%									
				Shaigan	Mionex	35	Qualified	1	48	48	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Sante	Megamox	35	Qualified	1	87.52	87.52		Conformity with Bid Evaluation Criteria
				Helix Pharma	Fotiflox	37	Qualified	1	95	95		Conformity with Bid Evaluation Criteria
384	Nettlimycin*	Eye Drops	0.3%	No Bid Received								
385	Ofloxacin Eye Drops	Eye Drops	0.3%									
				Sante	Optoflox	36	Qualified	1	70.94	70.94	Lowest Evaluated	Conformity with Bid Evaluation Criteria
386	Oxytetracycline*	Eye Ointment	0.5%	No Bid Received								
387	Tobramycin	Eye Drops	0.3%									
				Helix Pharma	Tobracin	38	Qualified	1	61	61	Lowest Evaluated	Conformity with Bid Evaluation Criteria
388	Fluoromethalone	Eye Drops	0.1%									
				Barrett Hodgson	FML Liquifilm	35	Qualified	1	50.24	50.24	Lowest Evaluated	Conformity with Bid Evaluation Criteria
389	Fluoromethalone	Eye Drops	0.25%	No Bid Received								
390	Moxifloxacin + Dexamethason	Eye Drops										
				Barrett Hodgson	Deximox	41	Qualified	1	114	114	Lowest Evaluated	Conformity with Bid Evaluation Criteria
391	Ofloxacin + Prednisolone	Eye Drops		No Bid Received								
392	Polymyxin, Bacitracin	Eye Ointment		No Bid Received								

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

393	Polymyxin, Bacitracin, Neomycin	Eye Ointment		No Bid Received								
394	Tobramycin , Dexamethasone	Eye Drops	0.1/0.3%									
				Helix Pharma	Tobracin-D	39	Qualified	1	72	72	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Sante	Santodex	35	Qualified	1	89.01	89.01		Conformity with Bid Evaluation Criteria
				Shaigan	Mydex	31	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
395	Olopatadine	Eye Drops	0.2%									
				Helix Pharma	Ogate Fort	35	Qualified	1	160	160	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Sante	Xepat forte Ophthalmic Solution	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
396	Phenylephrine	Eye Drops	10%	No Bid Received								
397	Diclofenac Sodium Eye Drops	Eye Drops	0.1%	No Bid Received								
398	Nepaphenac	Eye Drops	0.1%									
				Helix Pharma	Nafen	35	Qualified	1	103	103	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Sante	Nepac	35	Qualified	1	191.95	191.95		Conformity with Bid Evaluation Criteria
				Barrett Hodgson	Barinep	40	Qualified	1	110	110		Conformity with Bid Evaluation Criteria
				Shaigan	Nepafenec	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
399	Dextran + HPMC	Eye Drops	01%+.3%									
				Sante	Tears Forte	28	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
400	Polyvinyl Alcohol, Povidone	Eye Drops	1.4/0.6%									
				Barrett Hodgson	Tears Plus	35	Qualified	1	53.92	53.92	Lowest Evaluated	Conformity with Bid Evaluation Criteria
401	Proparacaine*	Eye Drops		No Bid Received								
402	Sodium Chloride	Eye Drops		No Bid Received								
403	Tropicamide	Eye Drops	0.5%	No Bid Received								
404	Acyclovir	Eye Ointment	0.03									
				Sante	Santovir Ophthalmic ointment	35	Qualified	1	121	121	Lowest Evaluated	Conformity with Bid Evaluation Criteria
405	Natamycin	Eye Drops	50mg									
				Sante	Matasan	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
406	Cyclosporin	Eye Drops		No Bid Received								
407	L Ornithine Aspartate	Infusion		No Bid Received								

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

408	L Ornithine Aspartate	Syrup		No Bid Received								
409	L Ornithine Aspartate ,Vit B	Syrup		No Bid Received								
410	Silymarin	Suspension	100mg	No Bid Received								
411	Silymarin	Tablet	200mg	No Bid Received								
412	Trypsin, Chymotrypsin	Tablet	100000IU									
				AGP	Chymoral Forte	45	Qualified	20	167.62	8.381	Lowest Evaluated	Conformity with Bid Evaluation Criteria
413	Hand Disinfectant	Solution	100ml	No Bid Received								
414	Hand Disinfectant	Solution	500ml	No Bid Received								
415	Instruments Disinfectant	Solution	2000ml	No Bid Received								
416	Povidone Iodine	Solution	60ml	No Bid Received								
417	Povidone Iodine	Solution	450ml	No Bid Received								
418	Surface Disinfectant	Solution	2000ml	No Bid Received								
419	Disodium Hydrogen	Liquid	1.315gm									
				PDH	Alkacitron	39	Qualified	1	45.1	45.1	Lowest Evaluated	Conformity with Bid Evaluation Criteria
420	Solifenacin	Tablet	5mg	No Bid Received								
421	Atracurium	Injection	25mg	No Bid Received								
422	Bupivacaine	Injection	5mg	No Bid Received								
423	Bupivacaine	Injection	7.5mg	No Bid Received								
424	Glycopyrrolate, Neostigmine	Injection	0.5mg	No Bid Received								
425	Isoflurane	Infusion	100ml	No Bid Received								
426	Ketamine*	Injection	500mg	No Bid Received								
427	Lignocaine	Injection	2%	No Bid Received								
428	Lignocaine	Gel	2%	No Bid Received								
429	Propofol	Infusion	1%	No Bid Received								

[Handwritten mark]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

430	Vit.K*	Injection	10mg	No Bid Received								
431	Tetnus Toxoid	Injection	5ml	No Bid Received								
432	Erythropoietin	Injection	10000IU									
				B&F Biosciences	Eritrogen	35	Qualified	1	649	649	Lowest Evaluated	Conformity with Bid Evaluation Criteria
433	Erythropoietin	Injection	4000IU									
				Macter	Epocan	36	Qualified	1	600	600	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				B&F Biosciences	Eritrogen	35	Qualified	6	2034	339		Conformity with Bid Evaluation Criteria
434	Methotrexate	Tablet	10mg	No Bid Received								
435	0.9% NaCl Solution	Infusion	100ml	No Bid Received								
436	0.9% NaCl Solution	Infusion	1000ml	No Bid Received								
437	0.9% NaCl Solution	Infusion	500ml	No Bid Received								
438	5% Dextrose Water	Infusion	1000ml	No Bid Received								
439	5% Dextrose Water	Infusion	500ml	No Bid Received								
440	Lactated Ringer Solution	Infusion	1000ml	No Bid Received								
441	Lactated Ringer Solution	Infusion	500ml	No Bid Received								
442	Paracetamole	Suspension	125mg	No Bid Received								
443	Levocetizine	Suspension	5mg	No Bid Received								
444	Phenaramine Meleat	Injection	22.7/mlmg	No Bid Received								
445	Lignocain,Euclyptol,Alcoh	Gel	20Grm	No Bid Received								
446	Theophylline	Capsules	200mg	No Bid Received								
447	Tobramycin+Dexamethso n	Ear Drops	0.1%	No Bid Received								
448	Tobramycin+Dexamethso n	Ear Drops	0.3%	No Bid Received								
449	Estradiol Valerate+Hydroxyprogest iron Carpro	Injection	5mg+250mg 2ml									
				Bayer Pakistan	Gravibinan	46	Qualified	1	305.97	305.97	Lowest Evaluated	Conformity with Bid Evaluation Criteria

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCUREMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

450	Pseudoephedrine 30mg + chlorophenamine Maleate 1mg + Dextrometharphin 10mg	Syrup	120ml									
				The searle	Hydrilin DM	42	Qualified	1	56.3	56.3	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Pharmatec	Reltus DM	42	Qualified	1	71.72	71.72		Conformity with Bid Evaluation Criteria
451	Paracetamol 325mg +	Syrup	120mlmg	No Bid Received								
452	Pholcodin 1.5mg+ Promethazine 1.5mg	Elixer	mg	No Bid Received								
453	Terbutaline+Guafenesin	Syrup	1.5/66.5mg	No Bid Received								
454	Cyclobenzaprine HCL	Tablet	10mg	No Bid Received								
455	Citicolin	Injection	250mg/2ml mg	No Bid Received								
456	Vortioxetine	Tablet	10mg									
				Kaizen	Evortiox	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
457	Vonoprazan	Tablet	10mg									
				Hilton	Voniza	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Kaizen	Vonocab	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
458	Vonoprazan	Tablet	20mg									
				Hilton	Voniza	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Kaizen	Vonocab	32	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
459	Pholoroglucinol 40mg, Trimethylphologucinol 0.04mg	Injection	40mg+0.4mg									
				AGP	Anafortan Plus	45	Qualified	6	383.31	63.885	Lowest Evaluated	Conformity with Bid Evaluation Criteria
460	Pholoroglucinol 80mg, Trimethylphologucinol 80mg	Tablet	80mg+80mg									
				AGP	Anafortan Plus	45	Qualified	30	411.98	13.733	Lowest Evaluated	Conformity with Bid Evaluation Criteria
461	Empagliflazocin	Tablet	25mg									
				FerozSons	Empagen	35	Qualified	14	209.3	14.95	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Xenglu	36	Qualified	14	276.68	19.763		Conformity with Bid Evaluation Criteria

[Handwritten signatures and initials on the right margin]

DETAILED FINANCIAL EVALUATION FORM OF PROCURMENT OF MEDICINES FOR THE FINANCIAL YEAR 2022-2023

				AGP	Truglif	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
				Highnoon	Diagard	30	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
462	Dapazgliflazocin	Tablet	5mg									
				Highnoon	Daploz	35	Qualified	14	180.8	12.914	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Dapa	37	Qualified	14	190.61	13.615		Conformity with Bid Evaluation Criteria
463	Dapazgliflazocin	Tablet	10mg									
				Highnoon	Daploz	38	Qualified	14	261.1	18.65	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Dapa	37	Qualified	14	283.69	20.264		Conformity with Bid Evaluation Criteria
				Helix Pharma	Quisha	29	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
464	Empazgliflazocin + Metformin	Tablet	12.5/500mg									
				FerozSons	Empagen-M	41	Qualified	14	168	12	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				AGP	Truglifmet	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
465	Empazgliflazocin + Metformin	Tablet	12.5/1000mg									
				FerozSons	Empagen-M	41	Qualified	14	191.25	13.661	Lowest Evaluated	Conformity with Bid Evaluation Criteria
				Hilton	Xenglumet	37	Qualified	14	235.03	16.788		Conformity with Bid Evaluation Criteria
				AGP	Truglifmet	33	Disqualified	-	-	-		Non-Conformity with Bid Evaluation Criteria
466	Empazgliflazocin + Metformin	Tablet	12.5/850mg									
				Hilton	Xenglumet	37	Qualified	14	235.03	16.788	Lowest Evaluated	Conformity with Bid Evaluation Criteria

Dr.Mehwish Khalid
Pharmacist

Dr.Nadia Hussain
Drug Store Officer

Dr.Zahid Hussain Burddi
Regional Procurement Officer
WAPDA Hospital Gujranwala